Impact of phytosterol supplementation on plasma lipoprotein(a) and free fatty acid (FFA) concentrations: A systematic review and meta-analysis of randomized controlled trials

Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1168-1175. doi: 10.1016/j.numecd.2019.07.011. Epub 2019 Jul 30.

Abstract

Background and aim: Although some earlier studies have indicated the effect of phytosterol (PS) supplementation on serum lipoprotein(a) (Lp(a)) and free fatty acid (FFA) concentration, findings are still conflicting. We aimed to assess the impact of PS supplementation on serum Lp(a) and FFA concentration through a systematic review and meta-analysis of available RCTs.

Methods and results: We performed a systematic search of all available RCTs conducted up to 21 February 2019 in the following databases: PubMed, Scopus, and Cochrane. The choice of fixed- or random-effect model for analysis was determined according to the I2 statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). Pooling of 12 effect sizes from seven articles revealed a significant reduction of Lp(a) levels following PS supplementation (MD: -0.025 mg/dl, 95% CI: -0.045, -0.004, p = 0.017) without significant heterogeneity among the studies (I2 = 0.0%, p = 0.599). Also, PS supplementation significantly lowered FFA (MD: -0.138 mg/dl, 95% CI: -0.195, -0.081, p = 0.000) without significant heterogeneity among the studies (I2 = 0.0%, p = 0.911). The results for meta-regression and sensitivity analysis were not significant.

Conclusion: The meta-analysis suggests that oral PS supplementation could cause a significant reduction in serum Lp(a) and FFA.

Keywords: Free fatty acid; Lipoprotein(a); Phytosterols; Randomized controlled trial; Supplementation.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adult
  • Biomarkers / blood
  • Dietary Supplements* / adverse effects
  • Down-Regulation
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Fatty Acids, Nonesterified / blood*
  • Female
  • Humans
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Lipoprotein(a) / blood*
  • Male
  • Middle Aged
  • Phytosterols / adverse effects
  • Phytosterols / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Biomarkers
  • Fatty Acids, Nonesterified
  • Hypolipidemic Agents
  • Lipoprotein(a)
  • Phytosterols